


A QUICK INTRODUCTION TO MEDICATIONS FOR OPIOID USE DISORDER (MOUD)



- ▶ Also called Medication-assisted Treatment (MAT)
- ▶ FDA-approved medications, which includes methadone, buprenorphine, and naltrexone
- ▶ Gold standard treatment approach for Opioid Use Disorder (OUD)
- ▶ Providers can prescribe buprenorphine via telehealth

- ▶ Delivered in Office-based Opioid Treatment (OBOT) or Opioid Treatment Program (OTP) setting
- ▶ Substance Abuse and Mental Health Services Administration (SAMHSA) and Oregon Health Authority (OHA) certify OTPs
- ▶ Decreases risk of infectious disease, reduces risk of opioid overdose, and increases an individual's overall well-being

HOW MOUD WORKS IN THE BRAIN




MOUD reduces opioid use and craving by attaching to the opioid receptors and blocking opioid activity in the brain

METHADONE

Dispensed only at **certified OTPs**

Daily liquid or tablet
Brand names: Methadose, Dolophine




Full agonist: Generates full opioid effect

BUPRENORPHINE

Prescribed in **any general medical setting**, including OBOTS, dispensed at OTPs

Monthly injection or **Daily** tablet or film
Brand names: Subutex, Suboxone, Sublocade




Partial agonist: Generates partial opioid effect

NALTREXONE

Prescribed in **any general medical setting**, including OBOTS, dispensed at OTPs

Monthly injection or **Daily** tablet
Brand names: Vivitrol, Revia



Full antagonist: Blocks effect of opioids


BUPRENORPHINE CERTIFICATION

In January 2023, the [Waiver Elimination](#) (MAT Act) passed, which removed the federal requirement that prescribers have a waiver to prescribe MOUD. The legislation expands universal access to MOUD treatment by allowing any prescriber with a current DEA registration (Schedule III authority) to prescribe buprenorphine.


METHADONE AND OTP UPDATE

In February 2024, SAMHSA revised the [regulations that guide OTPs](#) (42 CFR Part 8 Final Rule). The revisions aim to expand access and improve retention in MOUD treatment by removing outdated regulations and promoting compassionate, patient-centered approaches to care. Oregon's State Opioid Treatment Authority, Dr. John McIlveen, and other Oregon leaders are currently working on updating state-based recommendations and policies based on these revisions. Oregon-based revisions should be available by the end of 2024.

OPIOID USE DISORDER COUNTS & OPIOID TREATMENT PROGRAMS



Among Oregonians who used medical services from January – December 2022, **44,331** had an OUD diagnosis.



Most OTPs are concentrated along the Interstate-5 (I-5) corridor serving Oregon’s 4 largest metro areas – Portland, Salem, Eugene, and Medford. **Coastal, rural, and frontier communities in Oregon are severely lacking in access to MOUDs and other OUD treatment.**

MEDICATIONS FOR OPIOID USE DISORDER DATA

METHADONE


- ▶ As of spring 2022, there are more than 10,000 active methadone patients at Oregon OTPs

BUPRENORPHINE

- ▶ Of the 12,000 Oregon providers that are DEA certified, only 1,081 (9.0%) dispensed a buprenorphine prescription. Of those prescribing, 82.0% wrote more than one prescription
- ▶ Among the 44,331 people diagnosed with OUD from January – December 2022, 15,711 (35.4%) patients were dispensed buprenorphine, a 7.5% increase from the previous year

NALTREXONE

- ▶ Among the 44,331 people diagnosed with OUD from January – December 2022, 1,079 (2.4%) patients were dispensed oral naltrexone, a 0.2% increase from the previous year



TAKE AWAYS

- ▶ Rates of OUD and co-occurring OUD and stimulant use disorder are high in Oregon.
- ▶ Despite the removal of the waiver requirement to prescribe buprenorphine, most eligible prescribers are not prescribing buprenorphine even though the need is high.
- ▶ OHA is committed to implementing state policies to expand access and improve retention in MOUD treatment. Federal requirement revisions have created opportunities for updating policies.